ABBV vs GILD

AbbVie Inc. against Gilead Sciences — live side-by-side technical comparison.

Prices as of 2026-11-09T21:03:43+00:00 UTC · updates daily

Who leads right now

GILD leads 5 of the 7 windows we measure — over 1 month ABBV is +6.1% and GILD +12.0%; over year to date ABBV is +28.4% and GILD +38.0%. The ABBV/GILD price ratio stands at 1.7322, below its 50-day average of 1.7774, and above the 200-day average of 1.6975. A ratio above its own average means ABBV is gaining on GILD; on this reading the recent edge belongs to GILD.

ABBV/GILD over the last year

ABBV/GILD price ratio · dashed: its 50- and 200-day lines · ratio above its 50-day line = ABBV gaining on GILD
1.3941.6081.8232.037
Both rebased to 100 on 2025-11-07
100108.2128.7146.6ABBVGILD
Ask
Compare ABBV and GILD: which has been stronger over the last year, and where does each stand against its 200-day average? Ask the analyst about this pair →

Performance side by side

ABBVGILD
Price$293.30 $169.32
1 day +0.7% +1.5%lead
5 days +1.5%lead -0.6%
1 month +6.1% +12.0%lead
6 months +45.5%lead +28.9%
Year to date +28.4% +38.0%lead
1 year +33.8% +42.5%lead
2 years +47.0% +75.3%lead
52-week position 91% of range 88% of range
52-week range $190.75–$302.93 $116.88–$176.58
vs 50-day average above $272.70 above $153.51
vs 200-day average above $239.31 above $141.13
RSI (14) 61 63
Market cap$514.9B$207.0B
Analyst target $310.65 (+6.6%) $174.77 (+4.7%)
Analysts2626
ConsensusBuyBuy
Next earnings Oct 30, 2026 Oct 29, 2026

Where each one stands

ABBV — AbbVie Inc.

ABBV trades at $293.30, above its 50-day average of $272.70, and above the 200-day at $239.31. It sits at 91% of its 52-week range ($190.75–$302.93); 14-day RSI is 61, in neutral territory; an average session moves it about 2.6%. For levels, the first level overhead is $294.89 (0.5% away) and the first support below is $275.00 (6.2% down). On the checklist the page runs for every asset, 5 of 6 checks read bullish — the lean is bullish.

GILD — Gilead Sciences

GILD trades at $169.32, above its 50-day average of $153.51, and above the 200-day at $141.13. It sits at 88% of its 52-week range ($116.88–$176.58); 14-day RSI is 63, in neutral territory; an average session moves it about 3.2%. For levels, the first level overhead is $174.48 (3.0% away) and the first support below is $153.51 (9.3% down). On the checklist the page runs for every asset, 5 of 6 checks read bullish — the lean is bullish.

Which one moves harder

GILD is the more volatile of the two — an average session moves it 3.2% against 2.6% for ABBV, so an identical position size carries roughly 1.2× the daily risk.

What would change the picture

The comparison turns on those levels: ABBV clearing $294.89 or losing $275.00; GILD clearing $174.48 or losing $153.51. Until one of them gives way, the relative reading above stands.

Questions people ask about ABBV vs GILD

Which is performing better right now, ABBV or GILD?
Over the past month ABBV is +6.1% and GILD is +12.0%, so GILD is ahead on that window. Year to date the figures are +28.4% for ABBV and +38.0% for GILD.
Which has done better over the last year, ABBV or GILD?
Over the last year ABBV is +33.8% and GILD is +42.5%, so GILD is ahead on that window. Over two years it is +47.0% against +75.3%.
Is ABBV or GILD more volatile?
GILD is the more volatile of the two — an average session moves it 3.2% against 2.6% for ABBV, so an identical position size carries roughly 1.2× the daily risk.
What are the key levels for ABBV and GILD?
ABBV: resistance $294.89, support $275.00; GILD: resistance $174.48, support $153.51. Levels come from recent swing zones and round numbers, recomputed daily.
When do ABBV and GILD report next?
ABBV: Oct 30, 2026. GILD: Oct 29, 2026. Earnings reset both the trend and the levels above, so a comparison made today is only good until the next report.
What does the ABBV/GILD ratio mean?
It is simply ABBV's price divided by GILD's — 1.7322 today. When the ratio rises, ABBV is outperforming; when it falls, GILD is. Comparing it to its own 50- and 200-day averages shows whether the current leadership is new or long-standing.

Full technical briefs

ABBV →
AbbVie Inc.
Full technical brief: trend, levels, chart, news
GILD →
Gilead Sciences
Full technical brief: trend, levels, chart, news

Related comparisons

JNJ vs LLYABBV vs LLYLLY vs MerckLLY vs UNHLLY vs TMOAMGN vs LLYGILD vs LLYABT vs LLY